eli lilly phase 3 trial retatrutide just announced striking results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% eli lilly phase 3 trial

Timeline: noticeable regain begins within 24 weeks as appetite returns

BMI 27 with weight-related conditions, such as: Type 2 diabetes or prediabetes Hypertension High cholesterol Sleep apnea Fatty liver disease (NAFLD) PCOS Insulin resistance Patients in this range may be candidates because GLP-1 medications act on pathways related to blood sugar, appetite, and metabolic regulation

doi: 10.3390/life13101947 80 MerolaJFMeasePKivitzASattarNCoatesLCAletahaDet al

This technology satisfies a growing patient demand and the need for alternative non-ablative (abrasive), non-invasive treatments by using ultrasound energy that works by heating up the underlying skin tissue without harming the skin's surface

39,95 Prices may be subject to local taxes which are calculated during checkout Similar content being viewed by others Data availability The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request